Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372772 | 0.81 | CHRNA7 (0.54) | CHRNA7MAPTHTR3ACHRNA3 | |
| SCHEMBL4027798 | 0.76 | CHRNA7 (0.58) | HCAR2CHRNA7ALDH1A1MAPT | |
| SCHEMBL13887379 | 0.76 | CHRNA7 (0.58) | HCAR2CHRNA7ALDH1A1MAPT | |
| SCHEMBL4030339 | 0.76 | GUSB (0.41) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5218906 | 0.73 | HRH3 (0.69) | HCAR2 | |
| SCHEMBL17570418 | 0.73 | HRH3 (0.66) | — | |
| SCHEMBL14409441 | 0.73 | HRH3 (0.69) | HCAR2 | |
| SCHEMBL4029530 | 0.72 | ALDH1A1 (0.55) | HCAR2CHRNA7ALDH1A1MAPTHTR3A | |
| SCHEMBL13887190 | 0.72 | ALDH1A1 (0.55) | HCAR2CHRNA7ALDH1A1MAPTHTR3A | |
| SCHEMBL13887191 | 0.71 | CHRNA7 (0.46) | CHRNA7HTR3ACHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1539764-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016616-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | CHRNA7, CHRNB1, CHRNA1 | HCAR2 145/4885CHRNA7 1/4885ALDH1A1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.